The Singapore facility is part of Sanofi's 900 million euro investment to develop two new EVFs globally over five years. The ...

In a bid to bolster pandemic preparedness, Sanofi has opened a modular vaccine manufacturing plant in Tuas Biomedical Park, ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Clinical trials for a revolutionary vaccine to treat acne will be conducted by the National Skin Centre in partnership with ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

About 200 people with the condition will be recruited for the trial, which will start in 2025. Read more at straitstimes.com.

Sanofi's $595m Singapore facility, Modulus, leverages advanced technology for rapid, flexible vaccine production, bolstering ...

The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully ...